ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 824

Comparing Childhood- Versus Adult-Onset Polyarteritis Nodosa

Michele Iudici1, Pierre Quartier2, Christian Pagnoux3, Etienne Merlin4, Christian Agard5, Achille Aouba6, Pascal Roblot7, Pascal Cohen1, Benjamin Terrier1, Luc Mouthon1, Loïc Guillevin1 and Xavier Puéchal1, 1National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 2AP-HP, Institut des Maladies Génétiques (IMAGINE), and Université Paris-Descartes, Necker-Enfants Malades Hospital, Paris, France, 3Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 4CHU, Clermont-Ferrand, France, 5Nantes Hôtel Dieu, Nantes, France, 6Caen, Caen, France, 7CHU, Poitiers, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: polyarteritis nodosa and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To investigate differences between childhood (cPAN)- and adult-onset polyarteritis nodosa (aPAN) patients.

Methods: cPAN patients’ clinical findings at onset and outcomes were compared to those of aPAN patients from the French Vasculitis Study Group registry matched for year of enrollment and initial systemic versus cutaneous disease. Their information on medications, disease activity and damage were collected. Kaplan–Meier relapse-free survival curves and the log-rank test were used to analyze cPAN versus aPAN differences for predefined outcomes.

Results: Twenty-one children with systemic and 13 with cutaneous PAN were compared with 84 systemic- and 27 cutaneous-matched aPAN patients. Median follow-up exceeded 5 years for both groups. At study entry, mononeuritis multiplex was less frequent in systemic cPAN than systemic aPAN (P=0.04), and purpura and myalgias were less frequent in cutaneous cPAN than cutaneous aPAN (P<0.03). During follow-up, systemic cPAN relapsed more often than matched systemic aPAN (P<0.0001), while relapse rates were similar for cutaneous disease (P>0.05). Mostly minor relapses, predominantly involving the skin, occurred in all 4 groups. At last visit, damage accrual was comparable for cPAN and aPAN patients, but fewer systemic cPAN patients were treatment-free (15% versus 42%; P=0.03). Two (6%) cPAN and 8 (7%) aPAN patients died.

Conclusion: Systemic PAN is equally severe in children and adults and carries a higher risk of relapse. The main cutaneous PAN features seem not to be influenced by age at disease onset.


Disclosure: M. Iudici, None; P. Quartier, Novartis and SOBI, 5,AbbVie, Lilly, Novartis and SOBI, 8,AbbVie, BMS, Novartis, Pfizer, Sanofi, 9,AbbVie, Novartis, Pfizer, SOBI, 9; C. Pagnoux, None; E. Merlin, None; C. Agard, None; A. Aouba, None; P. Roblot, None; P. Cohen, None; B. Terrier, None; L. Mouthon, None; L. Guillevin, None; X. Puéchal, None.

To cite this abstract in AMA style:

Iudici M, Quartier P, Pagnoux C, Merlin E, Agard C, Aouba A, Roblot P, Cohen P, Terrier B, Mouthon L, Guillevin L, Puéchal X. Comparing Childhood- Versus Adult-Onset Polyarteritis Nodosa [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/comparing-childhood-versus-adult-onset-polyarteritis-nodosa/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-childhood-versus-adult-onset-polyarteritis-nodosa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology